Alkem Laboratories Ltd Corporate Actions

Alkem Labs' Taloja Bioequivalence Center Clears USFDA Inspection

 Copy Link

This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.

Alkem Laboratories Q3 Profit Rises 5% YoY

 Copy Link

The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.

Alkem Launches Kojiglo Serum in India for Hyperpigmentation Treatment

 Copy Link

The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.

Alkem Labs Q2 Profit Rises 11% to ₹689 Crore

 Copy Link

R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.

Cipla, Alkem Vie for SMT Acquisition

 Copy Link

This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.

Alkem Partners with Sonnet for Diabetic Neuropathy Drug in India

 Copy Link

Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.

Alkem Laboratories’ equity worth ₹487 Crore change hands

 Copy Link

According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).